Literature DB >> 22961071

[HIV 2012 : research update].

G M N Behrens1.   

Abstract

HIV therapy is able to achieve complete viral suppression in up to 90% of patients. Thus, most patients will benefit from long-term effective and tolerable therapy combinations. Antiretroviral therapy, however, can still lead to side effects, is costly, and its success is dependent on sufficient health system resources and access to different drug combinations. Established tools in prevention and novel approaches to avoid spread of HIV infection are crucial to combat the epidemic. Recent advances in research about how drug regimens stop viral transmission ("treatment as prevention"), how the immune system defends against HIV (natural killer cells, broad neutralizing antibodies), and how cellular factors restrict viral replication are import milestones on the long way to stopping the global epidemic and to fostering vaccine development.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22961071     DOI: 10.1007/s00108-011-2973-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  21 in total

Review 1.  An overview of intracellular interactions between immunodeficiency viruses and their hosts.

Authors:  Paul D Bieniasz
Journal:  AIDS       Date:  2012-06-19       Impact factor: 4.177

2.  Prevention of HIV-1 infection with early antiretroviral therapy.

Authors:  Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming
Journal:  N Engl J Med       Date:  2011-07-18       Impact factor: 91.245

Review 3.  HIV cure and eradication: how will we get from the laboratory to effective clinical trials?

Authors:  Sharon R Lewin; Christine Rouzioux
Journal:  AIDS       Date:  2011-04-24       Impact factor: 4.177

4.  Lessons learned from HIV-1 vaccine trials: new priorities and directions.

Authors:  Andrew J McMichael; Barton F Haynes
Journal:  Nat Immunol       Date:  2012-04-18       Impact factor: 25.606

5.  The rates of HIV superinfection and primary HIV incidence in a general population in Rakai, Uganda.

Authors:  Andrew D Redd; Caroline E Mullis; David Serwadda; Xiangrong Kong; Craig Martens; Stacy M Ricklefs; Aaron A R Tobian; Changchang Xiao; Mary K Grabowski; Fred Nalugoda; Godfrey Kigozi; Oliver Laeyendecker; Joseph Kagaayi; Nelson Sewankambo; Ronald H Gray; Stephen F Porcella; Maria J Wawer; Thomas C Quinn
Journal:  J Infect Dis       Date:  2012-06-05       Impact factor: 5.226

6.  Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1.

Authors:  Maureen P Martin; Ying Qi; Xiaojiang Gao; Eriko Yamada; Jeffrey N Martin; Florencia Pereyra; Sara Colombo; Elizabeth E Brown; W Lesley Shupert; John Phair; James J Goedert; Susan Buchbinder; Gregory D Kirk; Amalio Telenti; Mark Connors; Stephen J O'Brien; Bruce D Walker; Peter Parham; Steven G Deeks; Daniel W McVicar; Mary Carrington
Journal:  Nat Genet       Date:  2007-05-13       Impact factor: 38.330

7.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Authors:  Susan P Buchbinder; Devan V Mehrotra; Ann Duerr; Daniel W Fitzgerald; Robin Mogg; David Li; Peter B Gilbert; Javier R Lama; Michael Marmor; Carlos Del Rio; M Juliana McElrath; Danilo R Casimiro; Keith M Gottesdiener; Jeffrey A Chodakewitz; Lawrence Corey; Michael N Robertson
Journal:  Lancet       Date:  2008-11-13       Impact factor: 79.321

Review 8.  Induction of immunity to human immunodeficiency virus type-1 by vaccination.

Authors:  M Juliana McElrath; Barton F Haynes
Journal:  Immunity       Date:  2010-10-29       Impact factor: 31.745

9.  Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.

Authors:  Morgane Rolland; Sodsai Tovanabutra; Allan C deCamp; Nicole Frahm; Peter B Gilbert; Eric Sanders-Buell; Laura Heath; Craig A Magaret; Meera Bose; Andrea Bradfield; Annemarie O'Sullivan; Jacqueline Crossler; Teresa Jones; Marty Nau; Kim Wong; Hong Zhao; Dana N Raugi; Stephanie Sorensen; Julia N Stoddard; Brandon S Maust; Wenjie Deng; John Hural; Sheri Dubey; Nelson L Michael; John Shiver; Lawrence Corey; Fusheng Li; Steve G Self; Jerome Kim; Susan Buchbinder; Danilo R Casimiro; Michael N Robertson; Ann Duerr; M Juliana McElrath; Francine E McCutchan; James I Mullins
Journal:  Nat Med       Date:  2011-02-27       Impact factor: 53.440

10.  HIV-1 adaptation to NK-cell-mediated immune pressure.

Authors:  Galit Alter; David Heckerman; Arne Schneidewind; Lena Fadda; Carl M Kadie; Jonathan M Carlson; Cesar Oniangue-Ndza; Maureen Martin; Bin Li; Salim I Khakoo; Mary Carrington; Todd M Allen; Marcus Altfeld
Journal:  Nature       Date:  2011-08-03       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.